Loading...
Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma
Diffuse large B cell lymphoma (dlbcl) is an aggressive non-Hodgkin lymphoma, accounting for approximately 30% of lymphoma cases in Canada. Although most patients will achieve a cure, up to 40% will experience refractory disease after initial treatment, or relapse after a period of remission. In elig...
Na minha lista:
| Udgivet i: | Curr Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Multimed Inc.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6726277/ https://ncbi.nlm.nih.gov/pubmed/31548805 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.5421 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|